ReVision Therapeutics Obtains $500,000 New Financing

  • Feed Type
  • Date
  • Company Name
    ReVision Therapeutics
  • Mailing Address
    5626 Oberlin Drive San Diego, CA 92121
  • Company Description
    ReVision Therapeutics is focused on developing fenretinide for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in the elderly. There are currently no treatments for the dry form of AMD, which accounts for 90% of patients with the disease. AMD gradually destroys sharp, central vision, and is caused by the accumulation of A2E, a toxic byproduct of the visual cycle, in the retina. ReVision’s lead drug candidate, fenretinide, has been shown to reduce the accumulation of A2E in the retina and slow the growth of atrophic lesions, which precede vision loss.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor

Trending on Xconomy